Growth Metrics

KalVista Pharmaceuticals (KALV) EBT Margin (2014 - 2025)

KalVista Pharmaceuticals recorded quarterly EBT Margin of 101.65% in Q3 2025, down 128.99% quarter-over-quarter from 350.57% in Q2 2025.

KalVista Pharmaceuticals' EBT Margin history runs 8 years deep, the most recent figure standing at 101.65% for Q3 2025.

  • In Q3 2025, EBT Margin changed N/A year-over-year to 101.65%; the TTM figure through Jul 2025 stood at 145.18% (up 59623.0% YoY), while the FY2025 annual figure was 803.71%, down 69839.0% from the prior year.
  • EBT Margin came in at 101.65% for Q3 2025 at KalVista Pharmaceuticals, down from 350.57% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 350.57% in Q2 2025 to a low of 101.65% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn -101.65%

Historic Data

Download Data 🔒
DateValue
Jul 31, 2025 -101.65%
Apr 30, 2025 350.57%
Apr 30, 2020 -224.74%
Jan 31, 2020 -783.26%
Oct 31, 2019 -224.08%
Jul 31, 2019 -266.37%
Apr 30, 2019 -371.80%
Jan 31, 2019 -152.62%
Oct 31, 2018 -83.85%
Jul 31, 2018 -186.12%
Apr 30, 2018 -60.00%
Jan 31, 2018 -185.84%
Oct 31, 2017 -526.71%
Jul 31, 2017 -5,678.13%
Apr 30, 2017 -4,457.02%
Jan 31, 2017 -3,270.16%
Oct 31, 2016 -2,038.07%
Jul 31, 2016 -523.69%
Mar 31, 2016 -94,342.86%
Dec 31, 2015 -80,800.00%
Sep 30, 2015 -71,314.29%
Jun 30, 2015 -83,342.86%
Mar 31, 2015 -74,057.14%
Sep 30, 2014 -39,240.00%
Jun 30, 2014 -50,360.00%
Mar 31, 2014 -33,583.33%